Brief Report|Articles in Press

Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib

Published:February 08, 2023DOI:

      Clinical Practice Points

      • Non–small-cell lung cancer harboring the duplex EGFR exon 21 L833V/H835L mutation is rare but exhibits sensitivity to EGFR TKI (tyrosine kinase inhibitor) therapy.
      • We report a case of this mutation in lung adenocarcinoma with leptomeningeal carcinomatosis which demonstrated an exceptional response to the EGFR TKI osimertinib.
      • Clinicians should be aware of the potentially actionable nature of the EGFR L833V/H835L mutation and consider treatment with a TKI such as osimertinib.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Zhuang Y
        • Xu J
        • Ma H
        • et al.
        A sequential method of epidermal growth factor receptor mutation detection reduces false negatives: a new case with doublet mutations of L833V and H835L in China.
        Clin Lung Cancer. 2013; 14: 295-300
        • Yang TY
        • Tsai CR
        • Chen KC
        • et al.
        Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.
        J Clin Oncol. 2011; 29: e468-e469
        • Qin BD
        • Jiao XD
        • Yuan LY
        • et al.
        The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review.
        OncoTargets Ther. 2018; 11: 4739
        • Cho JH
        • Lim SH
        • An HJ
        • et al.
        Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09).
        J Clin Oncol. 2020; 38: 488